Raymond James Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Raymond James Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,208	Closed	-$283K	–	1165
2021 Q4	$283K	Sell	3,208 -449	-12%	-$37K	0.01%	924
2021 Q3	$283K	Buy	3,657 +236	+7%	+$18.6K	0.01%	877
2021 Q2	$285K	Sell	3,421 -3	-0.1%	-$238	0.01%	875
2021 Q1	$259K	Sell	3,424 -442	-11%	-$36.1K	0.01%	894
2020 Q4	$339K	Buy	3,866 +445	+13%	+$35.3K	0.01%	714
2020 Q3	$260K	Sell	3,421 -88	-3%	-$8.9K	0.01%	756
2020 Q2	$433K	Buy	3,509 +232	+7%	+$23.1K	0.02%	511
2020 Q1	$277K	Buy	+3,277	New	+$282K	0.02%	572

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Raymond James Trust's BMRN Position: Q1 2022 in Review

Raymond James Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 3,208 shares — an estimated $283K sold.

Raymond James Trust first reported a position in BMRN in Q1 2020 and held it in 8 quarters. The position peaked at $433K in Q2 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Raymond James Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Raymond James Trust sold 3,208 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $283K.
Raymond James Trust first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Raymond James Trust's BioMarin Pharmaceuticals position peaked at $433K in Q2 2020.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Raymond James Trust's 13F filing for Q1 2022, filed 12 May 2022.